Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 3/2017

01-03-2017 | Urology – Letter to the Editor

Sunitinib tolerance and efficacy in patients with metastatic renal cell carcinoma according to ethnic and geographic factors

Authors: Jamal Zekri, Saba Imtiaz, Mubarak Al Mansour, Waseem Darwish

Published in: International Urology and Nephrology | Issue 3/2017

Login to get access

Excerpt

Editor, …
Literature
1.
Mir MH, Changal KH, Aziz SA, Bhat GM, Lone AR (2016) Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients? Int Urol Nephrol 48(11):1811–1816 (Epub 2016 Jul 23) CrossRefPubMed
2.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590. doi:10.​1200/​JCO.​2008.​20.​1293 CrossRefPubMedPubMedCentral
3.
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R (2015) Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 113(1):12–19. doi:10.​1038/​bjc.​2015.​196 CrossRefPubMedPubMedCentral
4.
5.
Ezz El Din M (2016) Utilization of sunitinib for renal cell cancer: an Egyptian University hospital experience. Asian Pac J Cancer Prev 17(7):3161–3166
6.
Barrios CH, Herchenhorn D, Chacón M, Cabrera-Galeana P, Sajben P, Zhang K (2016) Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma. OncoTargets Ther 9:5839–5845 (eCollection 2016) CrossRef
7.
Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A, ESMO Guidelines Working Group (2014) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):49–56. doi:10.​1093/​annonc/​mdu259 CrossRef
8.
Kawai Y, Osawa T, Kobayashi K, Inoue R, Yamamoto Y, Matsumoto H, Nagao K, Hara T, Sakano S, Nagamori S, Matsuyama H (2015) Factors prognostic for survival in Japanese patients treated with sunitinib as first-line therapy for metastatic clear cell renal cell cancer. Asian Pac J Cancer Prev 16(14):5687–5690CrossRefPubMed
9.
Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J (2016) Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget 7(19):27044–27054. doi:10.​18632/​oncotarget.​7395 PubMedPubMedCentral
Metadata
Title
Sunitinib tolerance and efficacy in patients with metastatic renal cell carcinoma according to ethnic and geographic factors
Authors
Jamal Zekri
Saba Imtiaz
Mubarak Al Mansour
Waseem Darwish
Publication date
01-03-2017
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2017
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1502-5

Other articles of this Issue 3/2017

International Urology and Nephrology 3/2017 Go to the issue

Urology - Original Paper

Vaporize, anatomically vaporize or enucleate the prostate? The flexible use of the GreenLight laser

Urology - Original Paper

Treatment of reno-ureteral colic by twelfth intercostal nerve block with lidocaine versus intramuscular diclofenac

Urology - Original Paper

Risk factors for intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma

Urology – Letter to the Editor

Issues in designing a randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome: Comment on Wang et al. Randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. Int Urol Nephrol. 2016;48:13–18

Nephrology - Original Paper

Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial

Nephrology - Original Paper

Hemodialysis-induced repolarization abnormalities on ECG are influenced by serum calcium levels and ultrafiltration volumes

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits